Therapeutic approaches to multiple sclerosis: an update on failed, interrupted, or inconclusive trials of immunomodulatory treatment strategies

BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
Jochen C UlzheimerHeinz Wiendl

Abstract

Multiple sclerosis (MS) continues to be a therapeutic challenge, and much effort is being made to develop new and more effective immune therapies. Particularly in the past decade, neuroimmunologic research has delivered new and highly effective therapeutic options, as seen in the growing number of immunotherapeutic agents and biologics in development. However, numerous promising clinical trials have failed to show efficacy or have had to be halted prematurely because of unexpected adverse events. Some others have shown results that are of unknown significance with regard to a reliable assessment of true efficacy versus safety. For example, studies of the highly innovative monoclonal antibodies that selectively target immunologic effector molecules have not only revealed the impressive efficacy of such treatments, they have also raised serious concerns about the safety profiles of these antibodies. These results add a new dimension to the estimation of risk-benefit ratios regarding acute or long-term adverse effects. Therapeutic approaches that have previously failed in MS have indicated that there are discrepancies between theoretical expectations and practical outcomes of different compounds. Learning from these defeats helps ...Continue Reading

References

Sep 1, 1991·The Journal of Experimental Medicine·P S LinsleyJ A Ledbetter
Jun 8, 1985·Lancet·W A SibleyK Clark
Jun 1, 1995·Neurology·B Arnason
Sep 1, 1993·European Journal of Immunology·F MattnerT Germann
Apr 29, 1998·Brain : a Journal of Neurology·B C KieseierH P Hartung
Apr 29, 1998·Nature·M Baggiolini
Oct 3, 1998·Clinical Pharmacology and Therapeutics·J D BowenA S Yu
Mar 17, 1999·The Journal of Clinical Investigation·T L SørensenR M Ransohoff
May 1, 1999·Journal of Autoimmunity·O S TargoniP V Lehmann
Jul 17, 1999·Journal of Neuroimmunology·A LigersO Olerup
Nov 24, 1999·Journal of the Neurological Sciences·T FukazawaK Tashiro
Jan 13, 2000·Current Opinion in Immunology·D E AndersonD A Hafler
Dec 2, 2000·Nature Medicine·B KwakF Mach
Mar 13, 2001·Annual Review of Immunology·B Salomon, J A Bluestone
Mar 23, 2001·Annals of Neurology·R Hohlfeld, H Wiendl
May 9, 2001·Neurology·R C Griggs
May 24, 2001·Current Opinion in Neurology·R Hohlfeld, H Wekerle
Jul 4, 2001·Nature Reviews. Neuroscience·V W YongD R Edwards
Jul 5, 2001·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·H Moses, S Sriram
Jul 11, 2001·Neurology·G L MancardiUNKNOWN Italian GITMO-NEURO Intergroup on Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis
Aug 8, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·G L CostaJ M Benson
Oct 18, 2001·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·A LugaresiD Gambi
Jan 5, 2002·JAMA : the Journal of the American Medical Association·A AscherioD J Hunter
Feb 6, 2002·The Journal of Clinical Investigation·Kenneth A Frauwirth, Craig B Thompson
Feb 23, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Asim DiabMichael K Racke
Feb 28, 2002·Proceedings of the National Academy of Sciences of the United States of America·Arthur A HurwitzJames P Allison
May 23, 2002·Brain : a Journal of Neurology·Veronika BrundulaV Wee Yong
Jun 5, 2002·Journal of Neuroimmunology·Torben L SørensenFinn Sellebjerg
Jul 3, 2002·Nature Reviews. Immunology·Ethan M Shevach
Jul 10, 2002·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Heinz Wiendl, Reinhard Hohlfeld
Aug 27, 2002·Journal of Neurology·A FassasUNKNOWN Autoimmune Disease Working Party of the EBMT (European Group for Blood and Marrow Transplantation)

❮ Previous
Next ❯

Citations

Aug 28, 2010·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Sven G MeuthHeinz Wiendl
Mar 2, 2013·Expert Review of Neurotherapeutics·Annika DeißMathias Buttmann
Apr 20, 2011·FEBS Letters·Petra EhlingSven G Meuth
Nov 14, 2015·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Stefan Bittner, Heinz Wiendl
Apr 11, 2012·European Journal of Immunology·Dàlia Raϊch-ReguéFrancesc E Borràs
Apr 11, 2012·European Journal of Immunology·Catharina C GrossHeinz Wiendl
May 2, 2013·Journal of Neuroscience Research·Amy J WisdomRhonda R Voskuhl
Apr 9, 2016·Expert Review of Neurotherapeutics·Steffen PfeufferSven G Meuth
May 17, 2011·Journal of Immunoassay & Immunochemistry·Zahra AmirghofranMaryam Esmaeilbeig
Aug 14, 2020·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Leoni RolfesSven G Meuth

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

International MS Journal
Christoph KleinschnitzHeinz Wiendl
Expert Review of Clinical Immunology
Masaaki Niino, Hidenao Sasaki
Neurology. Clinical Practice
Jiwon Oh, Paul W O'Connor
© 2021 Meta ULC. All rights reserved